Associated Papers
A retrospective study of the efficacy and safety of immune checkpoint inhibitors combined with chemotherapy for the treatment of SMARCA4-deficient thoracic tumors.
Wang B et al.
Translational Lung Cancer Research, 2024
39830761 (PubMed )
Supplement: tlcr-13-12-3460-supplementary.pdf
An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings.
Lu B et al.
Journal of Cancer, 2019
Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.
Fahiminiya S et al.
Oncotarget, 2016
26646792 (PubMed )
Supplement: oncotarget-07-1732-s001.pdf
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
Witkowski L et al.
Nature Genetics, 2014
Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Ramos P et al.
Rare Diseases (austin, Tex.), 2014
26942101 (PubMed )
Supplement: krad-02-01-967148-s001.zip › 967148_Supplementary_Materials › 967148_Supplemental_Table_1.xlsx › Supplemental_Table_1
Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.
Goodman AM et al.
Oncoimmunology, 0
Select a paper to view details